A Phase 2 interventional study of Nivolumab (3mg/kg) and Ipilimumab (1mg/kg) in TFE3-Rearranged Renal Cell Carcinoma, sponsored by Kidney Cancer Research Bureau. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Kidney Cancer Research Bureau · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.
Among the 64 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 51st largest by enrollment, is one of 5 that started in 2024, is one of 36 in phase 2, and was the 64th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.
Browse Carcinoma, Renal Cell studies →9 of the 64 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 70+
Mayo Clinic · Sites in United States
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 40 · Phase 3 8 · Phase 4 4
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 52 across the 64 interventional studies. Of the 35 that completed or were terminated, 19 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 64 have an industry lead sponsor. The 10 most frequent:
Kidney Cancer Research Bureau is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
12 studies in Carcinoma, Renal Cell by Kidney Cancer Research Bureau: 2 open now, 2 under way, none of them phase 3. Of 9 finished, 0 (0%) have results posted.
Among the 12 studies in Carcinoma, Renal Cell by Kidney Cancer Research Bureau, this one is the 11th largest by enrollment, is the only one that started in 2024, is one of 9 in phase 2, and was the 12th registered.
Kidney Cancer Research Bureau’s Carcinoma, Renal Cell studies by the year they started, since 2004.
9 of the studies testing nivolumab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04413123Bradley A. McGregor, MDCabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | 2026-12-20 |
| NCT02210117M.D. Anderson Cancer CenterNivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | 2026-12-31 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
| NCT04322955Mark SteinCYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition | 2027-05 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 64 studies testing nivolumab in Carcinoma, Renal Cell, from their registry updates:
Among Kidney Cancer Research Bureau’s 12 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
This randomized phase 2 study evaluates the efficacy and safety of nivolumab plus ipilimumab versus nivolumab plus cabozantinib as first-line treatment in patients with metastatic TFE-rearranged renal cell carcinoma. Patients are randomly assigned to one of the two treatment groups. Following disease progression, patients receive protocol-specified second-line treatment with lenvatinib plus everolimus. The study assesses treatment outcomes during first-line therapy and across the planned treatment sequence.
This prospective, randomized phase 2 pilot study evaluates two first-line nivolumab-based combinations followed by protocol-specified second-line lenvatinib plus everolimus in patients with metastatic TFE-rearranged renal cell carcinoma (RCC). The study assesses the activity and safety of each first-line regimen and explores outcomes across the planned treatment sequence.
Eligible patients have histologically confirmed metastatic TFE-rearranged RCC, with diagnostic confirmation by immunohistochemistry and/or fluorescence in situ hybridization, and no prior systemic therapy for metastatic disease. Additional eligibility criteria include an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 and intermediate- or poor-risk disease according to International Metastatic RCC Database Consortium (IMDC) criteria.
The study includes 12 patients randomly assigned in a 1:1 ratio to nivolumab plus ipilimumab or nivolumab plus cabozantinib, with six patients in each arm. Treatment is administered at standard doses and schedules for metastatic RCC and continues until disease progression or unacceptable toxicity. Upon progression, eligible patients are offered protocol-specified second-line lenvatinib plus everolimus, regardless of their initial treatment assignment. Computed tomography assessments are performed every 12 weeks.
The primary endpoint is investigator-assessed objective response rate during first-line treatment, evaluated separately in each randomized arm. Secondary endpoints include first-line progression-free survival, second-line objective response rate and progression-free survival, duration of response in both treatment lines, overall survival, and the incidence of grade 3 or higher treatment-related adverse events. Overall survival is measured from the initiation of first-line treatment to death from any cause.
The study uses a signal-seeking design in which each first-line arm is assessed independently against a prespecified null objective response rate of 5%. At least two objective responses among six patients constitute a positive activity signal. Response rates are reported with exact two-sided 95% confidence intervals, and time-to-event outcomes are analyzed descriptively. The study is not powered for formal between-arm comparisons.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nivolumab plus ipilimumab
Drug: Nivolumab (3mg/kg) · Drug: Ipilimumab (1mg/kg)
nivolumab plus cabozantinib
Drug: Nivolumab (3mg/kg) · Drug: Cabozantinib 60 MG
lenvatinib plus everolimus
Drug: Lenvatinib 18 MG · Drug: Everolimus 5 MG
Drug page: Nivolumab
Solution for intravenous infusion
Drug page: Ipilimumab
Solution for intravenous infusion
Tablets
Tablets
Tablets
First-Line Objective Response Rate (ORR)
The proportion of patients achieving a complete or partial response during first-line treatment, as assessed by the investigator according to RECIST version 1.1. ORR is evaluated separately in each randomized arm.
Time frame: 12 months
First-Line Progression-Free Survival (PFS)
Time from initiation of first-line treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
Time frame: 24 months
Second-Line ORR
The proportion of patients receiving second-line lenvatinib plus everolimus who achieve a complete or partial response, as assessed by the investigator according to RECIST version 1.1.
Time frame: 6 months
Second-Line PFS
Time from initiation of second-line lenvatinib plus everolimus to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
Time frame: 12 months
Duration of Response (DoR)
Time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
Time frame: 24 months
Overall Survival
Time from initiation of first-line treatment to death from any cause.
Time frame: 24 months
Incidence of Grade 3 or Higher Treatment-Related Adverse Events
The proportion of patients experiencing at least one grade 3 or higher treatment-related adverse event, graded according to NCI CTCAE version 5.0.
Time frame: 24 months
Ran from Feb 2024 to primary completion in Oct 2026, 32 months.
Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 32 months is below that.
Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab · Cabozantinib · Everolimus
Kidney Cancer Research Bureau